The global antibiotics market size is expected to reach USD 68.04 billion by 2030, registering a CAGR of 4.26% from 2023 to 2030, according to a new report by Grand View Research, Inc. High demand, increasing focus on antibiotic resistance programs, initiatives undertaken to avoid the misuse of antibiotics, and easy availability of generic drugs are responsible for market growth. The purchasing process of antibiotics is primarily influenced by physicians. The availability of multiple generic products provides buyers with easy switching options. In the case of institutional businesses, price discounts play an important role in the selection procedure. This can further reduce the profit margins of market players. However, buyers do not have these privileges in branded or patented products.
Furthermore, regulatory authorities have issued the guidelines for limited use of fluoroquinolones. Hence, the bargaining power of buyers is anticipated to be low over the forecast period. According to the State of World’s Antibiotics report, in 2021, the overall antimicrobial drug usage in India has increased sharply by 30%. Moreover, according to the CDC’s Antibiotics Usage in United States report, 2021 update, around 25 million prescriptions were dispensed from U.S. retail pharmacies. Among them, azithromycin was the leading formulation prescribed in 2021. Thus, the rising consumption pattern of antibacterial drugs is likely to fuel the market growth during the projected period. New product approvals and launches are expected to support market growth.
For instance, in June 2020, the U.S. FDA announced the approval of Recarbrio, a combination of cilastatin-imipenem and relebactam, for the treatment of ventilator-associated bacterial pneumonia and hospital-acquired bacterial pneumonia. The product was first approved for intra-abdominal infections and Urinary Tract Infections (UTIs) in July 2019. In the upcoming years, market growth is projected to be driven by governmental measures, such as the Generating Antibiotics Incentives Now Act, Global Research on Antimicrobial Resistance (GRAM) Project, and the Global Antibiotic Research & Development Partnership (GARDP). Moreover, these organizations are expected to propel the process of developing cutting-edge advanced medications and smoothen the approval process of antibiotic drugs.
Request a free sample copy or view report summary: Antibiotics Market Report
Owing to the dearth of commercial success of newly developed antibiotics, government & non-government bodies implemented certain strategies to incentivize antibacterial drug R&D activities
For instance, the government alliance with BARDA is supporting various companies to facilitate R&D activities in novel therapies for infectious diseases. BARDA has been associated with several pharmaceutical companies like AstraZeneca and GSK plc
The cell wall synthesis inhibitor segment held the largest share in 2022 owing to its wide spectrum of activity against gram-positive and gram-negative bacteria
The RNA synthesis inhibitors segment is anticipated to register the fastest CAGR from 2023 to 2030 due to a surge in product launches and R&D initiatives
The generic type segment held the largest share in 2022 due to the affordability of generic formulations and government initiatives to adopt generic drugs
The penicillin drug class segment led the market in 2022. However, the cephalosporin segment is anticipated to register the fastest CAGR from 2023 to 2030
Asia Pacific is expected to exhibit the fastest CAGR over the forecast period due to the rising investments by leading players and the high adoption of generic antibiotics in the region
Grand View Research has segmented the global antibiotics market based on type, drug class, action mechanism, and region:
Antibiotics Drug Class Outlook (Revenue, USD Million, 2018 - 2030)
Antibiotics Type Outlook (Revenue, USD Million, 2018 - 2030)
Antibiotics Action Mechanism Outlook (Revenue, USD Million, 2018 - 2030)
Cell Wall Synthesis Inhibitors
Protein Synthesis Inhibitors
DNA Synthesis Inhibitors
RNA Synthesis Inhibitors
Mycolic Acid Inhibitors
Antibiotics Regional Outlook (Revenue, USD Million, 2018 - 2030)
Middle East & Africa
List of Key Players of Antibiotics Market
Merck & Co., Inc.
Teva Pharmaceutical Industries Ltd.
Lupin Pharmaceuticals, Inc.
Melinta Therapeutics LLC
Shionogi & Co., Ltd.
KYORIN Pharmaceutical Co., Ltd.
GET A FREE SAMPLE
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
"The quality of research they have done for us has been excellent..."